IGC Pharma announces the addition of Pablo Arbelaez, Ph.D. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma’s lead therapeutic candidate targeting agitation in Alzheimer’s disease. Recent interim results from the IGC-AD1 Phase 2 trial demonstrated a clinically and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- India Globalization Capital: Breakthrough in Alzheimer’s Treatment Trial
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Supreme Court of Florida approves marijuana measure for November ballot
- Rising High: Exclusive talk with financial services firm Safe Harbor Financial
- IGC Pharma announces $3M unregistered private placement of common stock
